ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
08/07/2026
Voltar para busca
Dado oficial do USPTO
ZYLORION
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ZYLORION
ST13
US500000097102047Classe
5, 9, 29, 31, 35, 41, 42, 44
Pedido
97102047
Registro
8320275
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
59
Atualização mais recente
08/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 29, 31, 35, 41, 42, 44
Data de depósito
01/11/2021
Data de registro
30/06/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
30/06/2026
Última transação
08/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
CALGARY, CA
Examinador
MCCAULEY, BRENDAN D
Unidade examinadora
P10
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
ZYLORION HEALTH INC.
PsiloTec Health Solutions Inc.
Representantes
Charles G. Zug NELSON MULLINS RILEY & SCARBOROUGH LLP
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 29Classe 31Classe 35Classe 41Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Psychedelic medicines for the treatment of psychiatric diseasesmood disordersdepressionmood and emotional instability disorders; psychedelic medicines for the treatment of addiction disordersalcohol abusedrug abuseeating disordersgambling addiction and sex addiction; psychedelic medicines for the treatment of anxiety disorderssocial anxietygeneralized anxiety and panic attack disorder; psychedelic medicines for the treatment of psychological traumapost-traumatic stress disorderoccupational stress injurybullyingemotional traumaphysical traumawork traumafamily violence and grief; psychedelic medicines for the treatment of physical traumapost-burn injurypost-spinal-cord injuryadult post-amputationpost-brain injury and post-stroke; psychedelic medicines for the treatment of chronic painmigraineschronic back pain and chronic arthritis; psychedelic medicines for the treatment of cognitive diseasescognitive deteriorationearly dementia and age-associated memory impairment; psychedelic medicines for the treatment of neuropsychiatric disordersadult fetal alcohol spectrum disorderadult attention deficit disorderadult autismpost-stroke symptomsmultiple sclerosis and Parkinson's disease; psychedelic medicines for the treatment of sleep related disorderschronic fatigue syndromefatigue and insomnia; psychedelic medicines for the treatment of mental health problems experienced by indigenous and other marginalized communities; psychedelic medicines for the treatment of covid-19 symptoms and syndromes
Classe 9
Downloadable computer application software for mobile phones for clinical interactionsscheduling appointmentssubmitting feedbackmeasuring feedback from biometricssuch as pulse and heart ratestoring forms and questionnaires in connection with providing therapy services to individuals in the fields of psychiatric diseasesaddiction disordersanxiety disorderspsychological traumaphysical traumachronic paincognitive diseasesneuropsychiatric disorderssleep related disordersmental health problems experienced by indigenous and other marginalized communitiescovid-19 symptoms and syndromes; downloadable computer software for clinical interactionsscheduling appointmentssubmitting feedbackmeasuring feedback from biometricssuch as pulse and heart ratestoring forms and questionnaires in connection with providing therapy services to individuals in the fields of psychiatric diseasesaddiction disordersanxiety disorderspsychological traumaphysical traumachronic paincognitive diseasesneuropsychiatric disorderssleep related disordersmental health problems experienced by indigenous and other marginalized communitiescovid-19 symptoms and syndromes
Classe 29
Dried edible mushrooms
Classe 31
Fresh edible mushrooms
Classe 35
Data processing services of medical data relating to psychiatric diseasesaddiction disordersanxiety disorderspsychological traumaphysical traumachronic paincognitive diseasesneuropsychiatric disorderssleep related disordersmental health problems experienced by indigenous and other marginalized communitiescovid-19 symptoms and syndromes; compiling medical data for business purposes relating to psychiatric diseasesaddiction disordersanxiety disorderspsychological traumaphysical traumachronic paincognitive diseasesneuropsychiatric disorderssleep related disordersmental health problems experienced by indigenous and other marginalized communitiescovid-19 symptoms and syndromes
Classe 41
Provision of training in the fields of psychiatric diseasesaddiction disordersanxiety disorderspsychological traumaphysical traumachronic paincognitive diseasesneuropsychiatric disorderssleep related disordersmental health problems experienced by indigenous and other marginalized communitiescovid-19 symptoms and syndromes; provision of education servicesproviding courses of instructionclassesseminarsworkshopsconferences in the fields of psychiatric diseasesaddiction disordersanxiety disorderspsychological traumaphysical traumachronic paincognitive diseasesneuropsychiatric disorderssleep related disordersmental health problems experienced by indigenous and other marginalized communitiescovid-19 symptoms and syndromes; provision of training in the field of psychedelic medicines; provision of education servicesproviding courses of instructionclassesseminarsworkshopsconferences and training in the field of psychedelic medicines
Classe 42
Medical and scientific research and product development in the field of psychedelics; medical and scientific research in the fields of psychiatric diseasesaddiction disordersanxiety disorderspsychological traumaphysical traumachronic paincognitive diseasesneuropsychiatric disorderssleep related disordersmental health problems experienced by indigenous and other marginalized communitiescovid-19 symptoms and syndromes; providing medical and scientific research information in the field of clinical trials; conducting clinical trials for others in the fields of psychiatric diseasesaddiction disordersanxiety disorderspsychological traumaphysical traumachronic paincognitive diseasesneuropsychiatric disorderssleep related disordersmental health problems experienced by indigenous and other marginalized communitiescovid-19 symptoms and syndromes; laboratory scientific and medical research in the fields of psychiatric diseasesaddiction disordersanxiety disorderspsychological traumaphysical traumachronic paincognitive diseasesneuropsychiatric disorderssleep related disordersmental health problems experienced by indigenous and other marginalized communitiescovid-19 symptoms and syndromes; providing temporary use of non-downloadable computer software for clinical interactionsscheduling appointmentssubmitting feedbackmeasuring feedback from biometricssuch as pulse and heart ratestoring forms and questionnaires in connection with providing therapy services to individuals in the fields of psychiatric diseasesaddiction disordersanxiety disorderspsychological traumaphysical traumachronic paincognitive diseasesneuropsychiatric disorderssleep related disordersmental health problems experienced by indigenous and other marginalized communitiescovid-19 symptoms and syndromes; compiling medical and scientific research data in the fields of psychiatric diseasesaddiction disordersanxiety disorderspsychological traumaphysical traumachronic paincognitive diseasesneuropsychiatric disorderssleep related disordersmental health problems experienced by indigenous and other marginalized communitiescovid-19 symptoms and syndromes
Classe 44
Psychotherapy services; mental health therapy services for the treatment of psychiatric diseasesaddiction disordersanxiety disorderspsychological traumaphysical traumachronic paincognitive diseasesneuropsychiatric disorderssleep related disordersmental health problems experienced by indigenous and other marginalized communitiescovid-19 symptoms and syndromes; provision of information to others in the field of mental health; clinical mental health counselling services; compiling medical health information data in the fields of psychiatric diseasesaddiction disordersanxiety disorderspsychological traumaphysical traumachronic paincognitive diseasesneuropsychiatric disorderssleep related disordersmental health problems experienced by indigenous and other marginalized communitiescovid-19 symptoms and syndromes
Publicações
Histórico de despachos e eventos da marca no USPTO.
59 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
30/06/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
30/06/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/05/2026
PUBO
PUBLISHED FOR OPPOSITION
12/05/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/05/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/04/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/04/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/04/2026
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
13/04/2026
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
12/01/2026
GNSI
INQUIRY TO SUSPENSION E-MAILED
12/01/2026
CNSI
SUSPENSION INQUIRY WRITTEN
12/01/2026
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
17/10/2025
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
16/04/2025
GNSL
LETTER OF SUSPENSION E-MAILED
16/04/2025
CNSL
SUSPENSION LETTER WRITTEN
16/04/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/04/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/04/2025
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
15/04/2025
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
15/01/2025
GNSI
INQUIRY TO SUSPENSION E-MAILED
15/01/2025
CNSI
SUSPENSION INQUIRY WRITTEN
15/01/2025
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
17/07/2024
GNSL
LETTER OF SUSPENSION E-MAILED
17/07/2024
CNSL
SUSPENSION LETTER WRITTEN
17/07/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/07/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/07/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
16/07/2024
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
17/04/2024
GNSI
INQUIRY TO SUSPENSION E-MAILED
17/04/2024
CNSI
SUSPENSION INQUIRY WRITTEN
17/04/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
19/10/2023
GNSL
LETTER OF SUSPENSION E-MAILED
19/10/2023
CNSL
SUSPENSION LETTER WRITTEN
19/10/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/10/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/10/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
19/10/2023
ALIE
ASSIGNED TO LIE
19/10/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
22/05/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
23/02/2023
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
23/02/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
23/02/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23/02/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
22/02/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
22/02/2023
CNSI
SUSPENSION INQUIRY WRITTEN
22/02/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
25/08/2022
GNSL
LETTER OF SUSPENSION E-MAILED
25/08/2022
CNSL
SUSPENSION LETTER WRITTEN
25/08/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/08/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/08/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
19/08/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/08/2022
GNRT
NON-FINAL ACTION E-MAILED
12/08/2022
CNRT
NON-FINAL ACTION WRITTEN
12/08/2022
DOCK
ASSIGNED TO EXAMINER
10/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/11/2021
NWAP
NEW APPLICATION ENTERED
04/11/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ZYLORION ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.